Mr. Andre Godin reports

INTELGENX ANNOUNCES SHAREHOLDER APPROVAL OF FINANCING TRANSACTIONS

At IntelGenx Technologies Corp.'s meeting held earlier today, the shareholders voted to approve all proposals related to financing transactions involving atai Life Sciences AG previously disclosed by the company on Aug. 31, 2023.

In order for the company to proceed with the financing transactions not previously closed, shareholders were required to approve:

• The issuance of shares of common stock at prices which may be less than the minimum price permitted under the rules of the Toronto Stock Exchange (TSX);
• The issuance of shares in excess of 24.99 per cent of the issued and outstanding shares in connection with the financing transactions (the general shareholder approval);
• The issuance of shares to insiders of the company (as such term is defined in the policies of the Toronto Stock Exchange) in excess of 9.99 per cent of the issued and outstanding shares in connection with the financing transactions (the insider shareholder approval).

All matters were approved by the required majorities which, in the case of the general shareholder approval and the insider shareholder approval, excluded the votes attached to the shares beneficially owned, directly or indirectly, by atai, in accordance with the rules of the TSX and applicable securities regulations.

In addition, shareholders also approved an amendment to the certificate of incorporation of the company to increase the authorized common stock from 450 million shares to 580 million shares.

The financing transactions are further described in the proxy statement dated Oct. 16, 2023, available on-line, on SEDAR+ under the company's profile and under the company's profile on EDGAR.

About IntelGenx Corp.

IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films. IntelGenx's superior film technologies, including Versafilm, Disinteq, Vetafilm and transdermal Vevaderm, allow for next-generation pharmaceutical products that address unmet medical needs. IntelGenx's innovative product pipeline offers significant benefits to patients and physicians for many therapeutic conditions.

We seek Safe Harbor.